Harvoni (sofosbuvir+ledipasvir) and Daklinza (daclatasvir) in combination with Sovaldi (sofosbuvir) - Important Safety Information from Gilead Sciences International and Bristol Myers Squibb (BMS) as approved by the HPRA

Notice type: 3rd Party Publications

Date: 11/05/2015

Important Safety Information communication from Gilead Sciences International and Bristol Myers Squibb (BMS) on the risk of clinically significant arrhythmias when Harvoni (sofosbuvir+ledipasvir) or Daklinza (daclatasvir) in combination with Sovaldi (sofosbuvir) are given concomitantly with amiodarone.

Important Safety Information - Harvoni (sofosbuvir+ledipasvir) and Daklinza (daclatasvir) in combination with Sovaldi (sofosbuvir)